Human papillomavirus vaccine 9-valent (V503) - Merck

Drug Profile

Human papillomavirus vaccine 9-valent (V503) - Merck

Alternative Names: 9-valent HPV vaccine; 9-valent human papillomavirus vaccine; GARDASIL9; Human Papillomavirus 9-valent vaccine, Recombinant; Human papillomavirus vaccine - Merck; Multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine - V503; V-503

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Cervical cancer; Human papillomavirus infections; Vulvovaginal cancer
  • Registered Condylomata acuminata

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 25 Oct 2016 Registered for Human papillomavirus infections (Prevention, In adolescents, In children) in USA (IM) in October 2016
  • 25 Oct 2016 The US Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunisation Practices (ACIP) voted to recommend a 2-dose vaccination regimen of the HPV vaccine in males and females between 9-14 years of age
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top